Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Troriluzole

Troriluzole - 2 100mg capsules QD for the first two weeks.

DRUG

Placebo

Matching placebo - 2 140mg capsules QD from week two through week ten.

Trial Locations (73)

10036

Manhattan Behavioral Medicine, PLLC, New York

10312

Richmond Behavioral Associates, Staten Island

10549

Bioscience Research, LLC, Mount Kisco

11021

Bio Behavioral Institute, Great Neck

11229

Integrative Clinical Trials, LLC, Brooklyn

11516

Neurobehavioral Research, Inc, Cedarhurst

19063

Suburban Research Associates, Media

20877

CBH Health, Gaithersburg

21208

Pharmasite Research, Inc., Pikesville

30030

iResearch Atlanta, LLC, Decatur

31405

iResearch Savannah, Savannah

32763

Medical Research Group of Central Florida, Orange City

32789

Conquest Research LLC, Winter Park

32803

APG Research, LLC, Orlando

32807

Combined Research Orlando Phase I-IV, Orlando

32808

Omega Research Consultants, Orlando

33013

Research in Miami Inc, Hialeah

33015

Health Care Family Rehab & Research, Miami

33026

MedBio Trials, Pembroke Pines

33125

Central Miami Medical Institute, Miami

33134

Advanced Clinical Research Network, Coral Gables

33161

Behavioral Clinical Research, North Miami

33166

South Florida Research Phase I-IV , Inc., Miami Springs

33173

FIRC, Miami

33174

Florida Research Center, Inc., Miami

33319

Innovative Clinical Research, Inc., Lauderhill

33326

Neurobehaviorial Institute, Weston

33431

Boca Raton Medical Institute, Boca Raton

33613

Stedman Clinical Trials, Tampa

33803

Accel Research Sites, Lakeland

39232

Precise Research Centers, Flowood

45431

Clinical Inquest Center, Ltd, Beavercreek

48105

Michigan Clinical Research Institute PC, Ann Arbor

60123

Revive Research Institute, Elgin

60563

AMR-Baber Research, Inc, Naperville

60640

Uptown Research Institute, Chicago

63368

Psychiatric Care and Research Center, O'Fallon

66210

Collective Medical Research, Overland Park

74136

Central States Research, LLC, Tulsa

75243

Relaro Medical Trials, Dallas

76104

North Texas Clinical Trials, Fort Worth

77030

Baylor College of Medicine, Houston

77081

Texas Center for Drug Development, Inc., Houston

77459

Mt.Olympus Medical Research LLC, Missouri City

78759

BioBehavioral Research of Austin, Austin

83704

Northwest Clinical Trials, Boise

85012

IMA Clinical Research, Phoenix

85016

NoeisisPharma, LLC, Phoenix

85284

Metropolitan Neuro Behavioral Institute, Chandler

89102

Altea Research, Las Vegas

90064

Clarity Clinical Research, Los Angeles

90502

Collaborative Neuroscience Research, Torrance

90706

CITrials (Clinical Innovations), Bellflower

90720

Pharmacology Research Institute, Los Alamitos

91206

Behavioral Research Specialists, LLC, Glendale

91316

WR-PRI, LLC (Encino), Encino

91403

California Neuroscience Research Medical Group, Inc, Sherman Oaks

92056

Excell Research, Inc, Oceanside

92324

Axiom Research, LLC, Colton

92374

Anderson Clinical Research, Redlands

92688

NRC Research Institute, Orange

94305

Stanford University, Stanford

95124

Lumos Clinical Research Center, LLC, San Jose

98007

Northwest Clinical Research Center, Bellevue

06519

Yale University / Connecticut Mental Health Center, New Haven

06360

Comprehensive Psychiatric Care, Norwich

02114

Massachusetts General Hospital, Boston

02131

Boston Clinical Trials, Boston

01844

ActivMed Practices and Research, Methuen

01103

Sisu at RMG, Springfield

08009

Hassman Research Institute, Berlin

08755

Bio Behavioral Health, Toms River

02906

Comprehensive Psychiatric Care Providers, Providence

Sponsors
All Listed Sponsors
lead

Biohaven Pharmaceuticals, Inc.

INDUSTRY